Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. (HBIO) on March 6, 2026. The filing primarily addresses executive compensation arrangements and personnel changes, specifically the amendment of the CEO's employment agreement and the permanent appointment of the CFO.
Key Financial Metrics and Compensation Details
The filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. Instead, it details specific executive compensation figures:
- CEO Base Salary (John Duke): $515,000 annually.
- CEO One-Time Bonus: $100,000 contingent on the successful refinancing of the Company's credit facility (in lieu of the FY2025 annual bonus).
- CEO Annual Incentive: Up to 80% of base salary.
- CEO Equity Grant (2026 Target): 75,000 restricted stock units (post 1:10 reverse stock split).
- CFO Base Salary (Mark Frost): $375,000 annually.
- CFO Annual Incentive: Up to 60% of base salary.
- CFO Equity Grant (2026 Target): 30,000 restricted stock units (post 1:10 reverse stock split).
Material Changes and Personnel Actions
- CEO Agreement Amendment: John Duke's employment agreement was amended and restated, extending the term until July 16, 2027, with automatic two-year extensions thereafter.
- CFO Appointment: Mark Frost was appointed Chief Financial Officer and Treasurer effective March 6, 2026, transitioning from his role as Interim Financial Officer held since April 10, 2025.
- Corporate Action: A 1:10 reverse stock split is scheduled to take effect on March 13, 2026, affecting the calculation of equity grants.
Outlook, Risks, and Contingencies
The filing highlights a material contingency regarding the CEO's compensation: a $100,000 bonus is explicitly tied to the successful refinancing of the Company's credit facility. Additionally, both executive agreements include severance and acceleration of vesting benefits triggered by termination without cause, for good reason, or in connection with a change-in-control, subject to the execution of a general release of claims.
Investor Verification Checklist
- Verify the status of the Company's credit facility refinancing to determine the likelihood of the $100,000 CEO bonus payout.
- Confirm the effective date and implementation details of the 1:10 reverse stock split scheduled for March 13, 2026.
- Review the specific definitions of "termination without cause" and "good reason" in the attached employment agreements to assess potential severance liabilities.
- Monitor future filings for the actual issuance of the targeted restricted stock units (75,000 for CEO, 30,000 for CFO).